Skip to main navigation
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Scholar Rock, Inc. Logo

Scholar Rock, Inc.

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
Link to homepage Investors & Media Board of Directors Akshay Vaishnaw, M.D., Ph.D.

Investors and Media

Akshay Vaishnaw, M.D., Ph.D.

Main content section

Akshay

Akshay Vaishnaw, M.D., Ph.D.

President of R&D, Scholar Rock
Dr. Akshay Vaishnaw has served as a member of our board of directors since May 2019. Dr. Vaishnaw joined Alnylam Pharmaceuticals in 2006, and currently serves as Chief Innovation Officer and is a member of its Scientific Advisory Board. Prior to Alnylam, he held various positions of increasing responsibility in clinical research and business development at Biogen, Inc., mostly recently Senior Director, Translational Medicine. Dr. Vaishnaw received a BS from University College Cardiff, U.K., an MD from the University of Wales College of Medicine, U.K., and a PhD in molecular immunology from the University of London, U.K. He is a Fellow of the Royal College of Physicians, U.K. Dr. Vaishnaw also serves on the Board of Directors for Editas Medicine Inc., Hemab Therapeutics, and as a Venture Partner at Atlas Venture.

    Primary Sidebar

    Investor Menu

    • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media

    In this section

    Footer

    Scholar Rock, Inc.
    301 Binney Street, 3rd Floor
    Cambridge, MA 02142

    Phone: 857.259.3860
    info@scholarrock.com

    © 2026 All Rights Reserved
    • Community Guidelines
    • Expanded Access Policy
    • Privacy Policy
    • Terms of Use

    We are Scholar Rock.

    A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

    Learn More About Our Pipeline

    • Community Guidelines
    • Expanded Access Policy
    • Privacy Policy
    • Terms of Use
    Scholar Rock, Inc. Logo
    • Patients & Families
      • Areas of Focus
        • Spinal Muscular Atrophy
      • Patient Stories
      • Clinical Trials
      • Resources
      • Expanded Access
    • Our Company
      • Our Company
      • Mission & Vision
      • Newsroom
      • Careers
      • Management Team
      • Board of Directors
    • Our Science
      • Our Science
      • Platform
      • Publications & Posters
    • Our Pipeline
      • Neuromuscular and Obesity
        • Spinal Muscular Atrophy
      • Immuno-Oncology
        • Cancer (solid tumors)
        • Fibrotic Diseases
      • Hematology
        • Anemia
    • Investors & Media
      • Press Releases
        • Archived Press Releases
      • Events & Presentations
      • Corporate Governance
        • Management Team
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
      • Stock Information
        • Historical Stock Lookup
        • Investment Calculator
        • Analyst Coverage
      • Investor FAQs
      • Contact IR or Media
    • Careers
    • Newsroom
    • Contact Us